Last reviewed 2026-04-23 · How we verify

HIP2101

HIP2101 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histone and non-histone proteins to modulate gene expression and induce anti-tumor effects.

HIP2101 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histone and non-histone proteins to modulate gene expression and induce anti-tumor effects. Used for Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL).

At a glance

Mechanism of action

By inhibiting HDAC enzymes, HIP2101 increases acetylation of histones, leading to more open chromatin structure and altered transcription of genes involved in cell cycle arrest, differentiation, and apoptosis. This mechanism is particularly relevant in hematologic malignancies and solid tumors where epigenetic dysregulation drives disease progression.

Approved indications

• Peripheral T-cell lymphoma (PTCL)
• Cutaneous T-cell lymphoma (CTCL)

Common side effects

• Thrombocytopenia
• Anemia
• Nausea
• Diarrhea
• Fatigue

Key clinical trials

• Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis (PHASE3)
• Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HIP2101 CI brief — competitive landscape report
• HIP2101 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI